Margetuximab Expanded Access Program

NCT03133988 | Unknown

• 1 other identifier: MGAH22-EA
• Study Type: expanded_access
• Target: N/A
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of the Expanded Access program is to provide margetuximab to patients with pretreated HER2+ breast cancer for whom potential benefit justifies potential treatment risks.

Conditions

HER2-positive Breast Cancer; HER2-positive Carcinoma

Interventions

Margetuximab BIOLOGICAL

anti-HER2 monoclonal antibody

Also known as: MGAH22

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• TerSera may consider requests on a case-by-case basis from treating physicians for patients not otherwise eligible for margetuximab clinical studies.
• Treating physicians should consider approved therapies for a patient's disease, as well as ongoing clinical studies, before seeking expanded access use with an investigational agent.

Sponsors & Collaborators

• TerSera Therapeutics LLC: lead

MeSH Terms

Interventions

margetuximab

Study Design

• Study Type: expanded access
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 20, 2017
• First Posted: April 28, 2017
• Last Updated: February 14, 2025

Record last verified: 2025-02